Mesenchymal stem cells (MSCs) are known to exhibit immunomodulatory, anti-inflammatory, and pro-angiogenic properties, and therefore have the potential to improve the outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT) .The study is aimed to identify and evaluate the potential benefits of MSCs infusion during allogeneic HSCT, with regard to the engraftment, graft versus host disease (GVHD), post-transplant relapse and survival.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
120
Co-transplantation of MSCs during allogeneic HSCT
Union Hospital,Fujian Medical University
Fuzhou, Fujian, China
RECRUITINGSurvival Rate
Time frame: up to 2 years after HSCT
Cumulative Incidence of Graft-versus Host Disease
Time frame: up to 2 years after HSCT
Incidence of Systemic Infections
Time frame: up to 2 years after HSCT
Mean Time to Engraftment
Time frame: Baseline to engraftment, assessed minimally 28 days post transplant
Transplant-Related Mortality
Time frame: up to 1 months after HSCT
Rates of Relapse
Time frame: up to 2 years after HSCT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.